What's Happening?
New research from Cleveland Clinic, published in eClinicalMedicine, indicates that patients who discontinue injectable GLP-1 drugs like semaglutide or tirzepatide achieve the greatest long-term weight loss if they subsequently undergo bariatric surgery.
The study analyzed electronic health records of 20,486 Cleveland Clinic patients who used these medications for at least three months between 2021 and 2023. Patients who switched between semaglutide and tirzepatide, remained on their initial medication, or transitioned to other obesity treatments also experienced significant weight loss over a two-year follow-up period. In contrast, those who stopped treatment without further intervention showed the least weight loss and minimal improvements in blood sugar control and blood pressure. Lead author Hamlet Gasoyan, Ph.D., a researcher with Cleveland Clinic’s Center for Value-Based Care Research, is scheduled to present these findings at ObesityWeek 2026.
Why It's Important?
This study provides crucial insights for the growing number of U.S. adults using GLP-1 medications for weight loss, a figure that climbed to 11% in 2026 from 3% in 2024, according to the 2026 Gallup National Health and Well-Being Index. The findings address a significant clinical challenge: managing weight loss and metabolic health after patients discontinue GLP-1 drugs, often due to cost, insurance limitations, or side effects. By identifying bariatric surgery as the most effective follow-up strategy, and other continued treatments as beneficial, the research offers clear guidance for clinicians and patients. This could lead to more structured and effective long-term obesity management plans, potentially reducing the risk of weight regain and associated health complications like Type 2 diabetes and hypertension. The study highlights the need for personalized treatment approaches, moving beyond a 'one-size-fits-all' model for a complex chronic disease like obesity.
What's Next?
The findings are set to be presented by Dr. Hamlet Gasoyan at ObesityWeek 2026, which will likely spark further discussion and potentially influence clinical guidelines for obesity management. Healthcare providers are encouraged to use this research to inform patient-clinician discussions about alternative therapy options for individuals considering switching or stopping injectable semaglutide or tirzepatide. The study emphasizes that discontinuing GLP-1 medication does not have to mark the end of an obesity treatment journey, but rather a transition to other effective therapies. Future research will continue to explore this field, aiming to help patients select treatments based on individualized expected benefits, risks, and personal preferences. This ongoing research could lead to the development of more tailored and effective long-term weight management strategies.
Beyond the Headlines
The study underscores the chronic nature of obesity and the necessity for continuous, adaptive treatment strategies. The high rate of GLP-1 drug discontinuation, driven by factors like cost and side effects, highlights systemic issues within healthcare access and affordability. The research implicitly calls for broader insurance coverage for various obesity treatments, including bariatric surgery and other medications, to ensure patients can access the most effective care pathways. Furthermore, the findings could stimulate innovation in pharmaceutical development, encouraging the creation of more sustainable and tolerable long-term obesity medications. Ethically, the study reinforces the importance of shared decision-making between patients and clinicians, ensuring that treatment plans are aligned with individual needs and circumstances, and that patients are not left without viable options after discontinuing a primary medication.
